Stockreport

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) [Yahoo! Finance]

Polaryx Therapeutics, Inc.  (PLYX) 
PDF Polaryx Therapeutics, Inc. Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX-200 across multiple lysosomal storage disorder [Read more]